FDA Publishes User Fee Guidance
The agency published guidance about requests for Prescription Drug User Fee Act waivers, refunds, and reductions in user fees.
On June 20, 2018, FDA released guidance providing recommendations for requests for waivers, refunds, and reductions of user fees for drugs and biologics. The new guidance revises the 2011 guidance User Fee Waivers, Reductions, and Refunds for Drug and Biological Products.
These user fees are assessed under sections 735 and 736 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revised draft guidance describes the procedures for requesting waivers, refunds, or reductions of these fees. It also describes the process to follow if FDA denies a company’s request. Clarification on related issues such as user fee exemptions for orphan drugs is also provided.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
